Welcome to LookChem.com Sign In|Join Free

CAS

  • or

55781-25-4

Post Buying Request

55781-25-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

55781-25-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 55781-25-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,5,7,8 and 1 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 55781-25:
(7*5)+(6*5)+(5*7)+(4*8)+(3*1)+(2*2)+(1*5)=144
144 % 10 = 4
So 55781-25-4 is a valid CAS Registry Number.

55781-25-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name 6'-hydroxyl-ribostamycin

1.2 Other means of identification

Product number -
Other names (2R,3S,4R,5R,6S)-5-Amino-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-((2S,3R,4S,5R)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yloxy)-3-hydroxy-cyclohexyloxy]-2-hydroxymethyl-tetrahydro-pyran-3,4-diol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:55781-25-4 SDS

55781-25-4Downstream Products

55781-25-4Relevant articles and documents

Novel aminoglycosides and uses thereof in the treatment of genetic disorders

-

Page/Page column 20; 34-35, (2009/04/24)

A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders.

Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations

Nudelman, Igor,Rebibo-Sabbah, Annie,Shallom-Shezifi, Dalia,Hainrichson, Mariana,Stahl, Ido,Ben-Yosef, Tamar,Baasov, Timor

, p. 6310 - 6315 (2007/10/03)

A series of new derivatives of the clinically used aminoglycoside antibiotic paromomycin were designed, synthesized, and their ability to read-through premature stop codon mutations was examined in both in vitro translation system and ex vivo mammalian cultured cells. One of these structures, a pseudo-trisaccharide derivative, showed notably higher stop codon read-through activity in cultured cells compared to those of paromomycin and gentamicin.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 55781-25-4